Fibroadenoma in adolescent females after living donor liver transplantation. (29th May 2017)

• Record Type: Journal Article
• Authors: Tanaka, N.; Ueno, T.; Takama, Y.; Yamanaka, H.; Tazuke, Y.; Bessho, K.; Okuyama, H.
• Is Part Of: Pediatric transplantation. Volume 21:Number 6(2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-05-29
• Subjects: adolescent female -- cyclosporine -- fibroadenoma -- living donor liver transplantation; Transplantation of organs, tissues, etc. in children -- Periodicals; 617.95408305
• DOI: 10.1111/petr.12947
• Languages: English
• ISSNs: 1397-3142

Abstract

Abstract: Breast FA is the most common breast tumor diagnosed in young women. Female renal transplant recipients on CsA have an increased risk of developing FA. However, reports of FA after LDLT have not been described. Our objectives were to determine the incidence of FA, analyze risk factors for FA, and evaluate treatment strategies in adolescent females after LDLT. A total of 18 female patients aged 10‐19 years who underwent LDLT and survived at least one year after transplantation were enrolled in our study. The incidence of FA was 11.1%. To determine pre‐ or post‐transplant conditions that are associated with FA after transplantation, the patients were divided into two groups according to the presence or absence of FA: FA group (n=2) and non‐FA group (n=16). There were no differences in mean age at LDLT, mean age at breast evaluation, and mean duration between transplantation and breast evaluation between the two groups. However, there was a difference in the immunosuppressive regimen between the two groups. The FA group was maintained on CsA, whereas the non‐FA group was maintained on tacrolimus. CsA might be implicated in FA development in adolescent females after LDLT.